Shares of C.R. Bard, Inc. (BCR) Sees Large Inflow of Net Money Flow

C.R. Bard, Inc. (BCR) dropped by -0.43 or -1.03 points during the last session to $236.3 per share. One of the highlights of the day was the net money flow figure, which stood at $20.91 million even as the stock accepted $78.72 million in upticks but rejected $57.81 million in downticks. The up/down ratio for the last observation was a 1.36. The 1-week percentage change for the stock price is registered at -0.9%.A block transaction occurred with $12.49 million in upticks and $0 million in downticks while the up/down ratio was calculated to be 0. The stock witnessed a net inflow of $12.49 million at the end of the block trade.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of C. R. Bard, Inc. rose by 2.51% in the last five trading days and 5.3% for the last 4 weeks. C. R. Bard, Inc. is up 9.18% in the last 3-month period. Year-to-Date the stock performance stands at 5.3%. C.R. Bard, Inc. (NYSE:BCR) witnessed a decline in the market cap on Wednesday as its shares dropped 0.43% or 1.03 points. After the session commenced at $238.17, the stock reached the higher end at $238.64 while it hit a low of $232.11. With the volume soaring to 1,062,350 shares, the last trade was called at $236.3. The company has a 52-week high of $240.5899. The company has a market cap of $17,374 million and there are 73,526,324 shares in outstanding. The 52-week low of the share price is $177.47.

Company has reported several Insider transactions to the SEC, on Jan 12, 2017, John P Groetelaars (Group President) sold 573 shares at 235.00 per share price.On Jan 11, 2017, Frank Jr Lupisella (Vice President and Controller) sold 2,945 shares at 232.00 per share price.On Jan 3, 2017, Jim C Beasley (Group President) sold 4,709 shares at 225.00 per share price.

C R Bard Inc Last issued its quarterly earnings results on Jan 26, 2017. The company reported $2.77 EPS for the quarter, beating the analyst consensus estimate by $ 0.03. Analyst had a consensus of $2.74. The company had revenue of $967.10 million for the quarter, compared to analysts expectations of $955.59 million. The companys revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.43 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.C R Bard Inc was Upgraded by Raymond James on Jan 5, 2017 to Strong Buy, Price Target of the shares are set at $265.Company shares were Upgraded by Morgan Stanley on Jan 3, 2017 to Overweight, Raises Price Target to $ 260 from a previous price target of $240 .

C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. In addition, Bard offers a complete line of advanced Surgical Specialty products and services that address needs in hernia repair, performance irrigation, hemostasis, and other areas.

C.R.

Share this post

Leave a Reply